Ensuring Quality and Efficacy of GLP-1 Agonists: Analytical Challenges and Solutions in Therapeutic Peptide Production Glucagon-like peptide-1 (GLP-1) agonists represent an exciting class of drugs that have gained significant attention in recent years for their potential to treat type 2 diabetes mellitus (T2DM) and obesity

Current UK professional guidance emphasises: Patients should inform their surgical team and anaesthetist that they are taking a GLP-1 medication as soon as surgery is planned Healthcare professionals should specifically ask about GLP-1 use during preoperative assessment, as patients may not recognise these medications as relevant to their surgery The decision to continue or pause GLP-1 therapy should be made on an individual risk-based assessment , considering the type of surgery, the specific GLP-1 agent, dose escalation status, presence of gastrointestinal symptoms, and the patient's clinical circumstances Many patients can safely continue GLP-1 medications perioperatively with appropriate precautions, while those at higher risk may benefit from temporary cessation The Summary of Product Characteristics (SmPC) for GLP-1 medications notes the delayed gastric emptying effect, which anaesthetists consider when planning perioperative care

Trial-Based Protocol: The schedule below reflects the Phase 2 clinical trial protocol starting at 2mg
Phosphatidylserine, NAC, or Vitamin D: When to Prioritize If your ADHD symptoms worsen with stress, fatigue, or seasonal changes, consider checking vitamin D levels first and layering in NAC or PS for antioxidant and mitochondrial support
It is considered a conditionally essential nutrient because in some situations, the bodys demand for L-carnitine exceeds its capacity to make it